Velcade (Bortezomib) Consolidation After Transplant (VCAT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Janssen Scientific Affairs, LLC
Sponsor:
Information provided by (Responsible Party):
Janssen Scientific Affairs, LLC
ClinicalTrials.gov Identifier:
NCT01539083
First received: November 23, 2011
Last updated: July 14, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to determine if bortezomib when added to consolidation treatment with thalidomide and prednisolone leads to an improved response in patients with multiple myeloma who have undergone autologous stem cell transplant and initial treatment with bortezomib, cyclophosphamide, and dexamethasone.


Condition Intervention Phase
Multiple Myeloma
Drug: Thalidomide
Drug: Bortezomib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Randomised Trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Vs Thalidomide and Prednisolone Alone in Previously Untreated Subjects With Multiple Myeloma After Receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Induction and Autologous Stem Cell Transplant

Resource links provided by NLM:


Further study details as provided by Janssen Scientific Affairs, LLC:

Primary Outcome Measures:
  • The number and percent of patients with complete response (CR) + very good partial response (VGPR) [ Time Frame: After approximately 12 months of consolidation therapy ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Complete response (CR) rate [ Time Frame: From time of screening up to 12 months post-randomization ] [ Designated as safety issue: No ]
    Complete response (CR) is defined by international myeloma working group (IMWG) criteria for multiple myeloma.

  • Stringent complete response (sCR) rate [ Time Frame: From time of screening up to 12 months post-randomization ] [ Designated as safety issue: No ]
    Stringent complete response (sCR) is defined by IMWG criteria for multiple myeloma.

  • Progression-free survival (PFS) rate [ Time Frame: From time of randomization up to 3 years post-randomization ] [ Designated as safety issue: No ]
    Progression-free survival (PFS) is defined by IMWG criteria calculated as the time between randomization to disease progression or death (regardless of cause), whichever comes first.

  • Disease-free survival (DFS) rate [ Time Frame: From time of randomization up to 3 years post-randomization ] [ Designated as safety issue: No ]
    Disease-free survival (DFS) is defined by the duration from the start of CR to the time of relapse from CR. Disease-free survival applies only to subjects in CR.

  • Overall survival (OS) rate [ Time Frame: From time of randomization to up to 3 years post-randomization ] [ Designated as safety issue: No ]
    Overall survival (OS) is defined as the time between randomization and death (regardless of cause).


Estimated Enrollment: 220
Study Start Date: January 2012
Estimated Study Completion Date: February 2018
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Thalidomide
Thalidomide consolidation and prednisolone maintenance therapy
Drug: Thalidomide
Thalidomide: Type=1, unit=mg, number=100, form=tablet, route=oral use. Oral thalidomide consolidation will be administered for a maximum of 12 months or until disease progression along with Prednisolone: Type=1, unit =mg, number=50, form=tablet, route=oral use. Prednisolone maintenance therapy will be administered on alternate days continued indefinitely or until disease progression.
Experimental: Bortezomib + Thalidomide
Bortezomib + Thalidomide consolidation and prednisolone maintenance therapy.
Drug: Bortezomib
Type=1, unit=mg/ml, number=2.5, form= Solution for injection, route=Subcutaneous use. Bortezomib will be administered as a single subcutaneous injection at a concentration of 1.3 mg/m2 every 2 weeks for 32 weeks (16 doses) in addition to 100 mg daily oral thalidomide consolidation for a maximum of 12 months or until disease progression and 50 mg oral alternate-day prednisolone maintenance continued indefinitely or until disease progression.
Drug: Thalidomide
Type=1, unit=mg, number=100, form=tablet, route=oral use. 100 mg daily oral thalidomide consolidation (administered in addition to bortezomib) will be administered for a maximum of 12 months or until disease progression and 50 mg oral alternate-day prednisolone maintenance continued indefinitely or until disease progression.

Detailed Description:

This is an open-label (patients will know the identity of study treatments), randomized (patients will be assigned by chance to different treatments) study of bortezomib administered as consolidation therapy (therapy given once a remission is achieved) with thalidomide and prednisolone versus thalidomide and prednisolone alone in previously untreated patients with multiple myeloma. Multiple myeloma is a cancer of your plasma cells, a type of white blood cell present in your bone marrow. Patients in this study will receive initial therapy with bortezomib, cyclophosphamide, and dexamethasone (referred to as VCD induction therapy) and will undergo autologous stem cell transplant (ASCT) (a procedure where patients receive an infusion of immature blood cells [stem cells] from their own body to replenish the body's supply of healthy blood-forming cells) before randomization to one of two treatments: Treatment A (thalidomide for up to 12 months or until disease progression and prednisolone on alternate days continued indefinitely or until disease progression) or Treatment B (bortezomib for 32 weeks in addition to thalidomide up to 12 months or until disease progression and prednisolone on alternate days, continued indefinitely or until disease progression.

Throughout the study, the patient's response to therapy will be assessed according to protocol-defined efficacy evaluations and by implementing defined disease response criteria (International Myeloma Working Group [IMWG] criteria). Safety will be evaluated throughout the study. Follow up for progression-free survival (PFS) and overall survival (OS) will be conducted from time of randomization to 3 years post-randomization.

Two interim analyses are planned. The final analysis will be conducted after all patients have completed 12-month consolidation treatment phase or discontinued. The primary endpoint of number and percent of patients with complete response and very good partial response defined by IMWG criteria for multiple myeloma will be examined in the interim and final analyses after approximately 12 months of consolidation therapy. At the completion of the study, updated analyses of PFS and OS will be performed.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Previously diagnosed with multiple myeloma based on international myeloma working group (IMWG) criteria.
  • Meet the pretreatment laboratory criteria as specified in the study protocol at and within 21 days before baseline (Day 1 of Cycle 1, before bortezomib administration for induction).
  • Have ECOG status 0-2.
  • Men and women must practice an appropriate method of birth control as specified in the study protocol from signing of the informed consent form though to the 12-month visit/early termination visit.

Exclusion criteria:

  • Has previously received treatment for multiple myeloma (including prior therapy with radiation or pulsed dexamethasone) as specified in the study protocol.
  • Has a history of any other malignancy within 5 years before enrolment as specified in the study protocol.
  • Has had major surgery as specified in the study protocol within 30 days before enrolment.
  • Had a myocardial infarction within 6 months of enrolment or has New York Heart Association (NYHA) Class III or IV heart failure (or other clinically significant cardiac medical history as specified in the study protocol).
  • Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01539083

Contacts
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: JNJ.CT@sylogent.com

Locations
Australia
Recruiting
Adelaide, Australia
Withdrawn
Auchenflower, Australia
Withdrawn
Box Hill, Australia
Recruiting
Camperdown, Australia
Withdrawn
Fremantle, Australia
Withdrawn
Garran, Australia
Recruiting
Geelong, Australia
Withdrawn
Gosford, Australia
Completed
Greenslopes, Australia
Recruiting
Heidelberg, Australia
Recruiting
Herston, Australia
Recruiting
Malvern, Australia
Recruiting
Melbourne, Australia
Recruiting
Nedlands, Australia
Recruiting
Newcastle, Australia
Withdrawn
Perth, Australia
Recruiting
Prahran, Australia
Recruiting
Sydney, Australia
Recruiting
Westmead, Australia
Recruiting
Woodville South, Australia
Recruiting
Woolloongabba, Australia
China
Active, not recruiting
Beijing, China
Recruiting
Guangzhou, China
Active, not recruiting
Shanghai, China
Active, not recruiting
Tianjin, China
Korea, Republic of
Active, not recruiting
Busan, Korea, Republic of
Recruiting
Busan, Korea, Republic of
Recruiting
Daegu, Korea, Republic of
Withdrawn
Daejeon, Korea, Republic of
Recruiting
Hwasun Gun, Korea, Republic of
Recruiting
Ulsan, Korea, Republic of
Sponsors and Collaborators
Janssen Scientific Affairs, LLC
Investigators
Study Director: Janssen Asia-Pacific Medical Affairs Clinical Trial Janssen Asia-Pacific Medical Affairs
  More Information

Additional Information:
No publications provided

Responsible Party: Janssen Scientific Affairs, LLC
ClinicalTrials.gov Identifier: NCT01539083     History of Changes
Other Study ID Numbers: CR018751, 26866138-MMY-2073
Study First Received: November 23, 2011
Last Updated: July 14, 2014
Health Authority: Australia: National Health and Medical Research Council
Australia: Department of Health and Ageing Therapeutic Goods Administration
Republic of Korea: Food and Drug Administration

Keywords provided by Janssen Scientific Affairs, LLC:
Multiple Myeloma
Bortezomib
VELCADE
Consolidation therapy
Subcutaneous
Thalidomide
Prednisolone
Autologous stem cell transplant (ASCT)
VELCADE, cyclophosphamide, dexamethasone (VCD) induction therapy

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Cyclophosphamide
Thalidomide
Bortezomib
Dexamethasone
Prednisolone
Methylprednisolone Hemisuccinate
Methylprednisolone acetate
Prednisolone acetate
Methylprednisolone
Prednisolone hemisuccinate
Prednisolone phosphate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents

ClinicalTrials.gov processed this record on August 18, 2014